Trial Profile
A Phase II multi-Center, randomized study of Bortezomib-Dexamethasone re-treatment at biochemical relapse vs observation in Relapsed/Refractory Multiple Myeloma patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology